Citius Pharmaceuticals is trading approximately 10% down at $0.57 as traders take profits following a sharp multi-day rally tied to LYMPHIR’s commercialization momentum.
- The stock had previously surged on news that Citius Oncology expanded its commercial organization and reported $1.7 million in quarterly net revenue.
- Short-term momentum appears to be unwinding today in the absence of fresh company-specific catalysts and amid broader weakness in healthcare shares.